Cargando…

An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine

INTRODUCTION: With the approval of the adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) in October 2017, GSK established enhanced safety surveillance measures to allow prompt identification of potential safety signals not observed during clinical development. In Germany, cases of vesicular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirrotta, Paola, Tavares-Da-Silva, Fernanda, Co, Maribel, Lecrenier, Nicolas, Hervé, Caroline, Stegmann, Jens-Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626369/ https://www.ncbi.nlm.nih.gov/pubmed/34622421 http://dx.doi.org/10.1007/s40264-021-01118-3

Ejemplares similares

2776. Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2019)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
por: Thompson, Hallie, et al.
Publicado: (2021)

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

Brief communication: A 61-year-old woman with vesicular eruption after varicella zoster vaccination
por: Ganacias, Karen, et al.
Publicado: (2016)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
por: Fiore, Joseph, et al.
Publicado: (2021)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
por: Giannelos, Nikolaos, et al.
Publicado: (2022)

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

Generalized bullous fixed-drug eruption secondary to the influenza vaccine
por: Byrd, Rachel Chikowski, et al.
Publicado: (2018)

114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

MRNA COVID-19 VACCINE-ASSOCIATED BULLOUS FIXED DRUG ERUPTION
por: Imam, S., et al.
Publicado: (2022)

Cases of Varioloid Eruption Occurring Subsequent to Vaccination
por: Wade, R.
Publicado: (1824)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination
por: Tomayko, Mary M., et al.
Publicado: (2021)

Bullous Cutaneous Eruption due to Extravasation of Acyclovir in an Adolescent with Acute Lymphoblastic Leukemia
por: Sarıca, Abdurrahman
Publicado: (2012)

Abrupt Bullous Cutaneous Eruption After Application of Tacrolimus Ointment and Sun Exposure
por: Spigariolo, Cristina Beatrice, et al.
Publicado: (2023)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS
por: Naficy, A., et al.
Publicado: (2023)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020)

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
por: Bastidas, Adriana, et al.
Publicado: (2019)

Case Report and Review of the Literature: Bullous Skin Eruption After the Booster-Dose of Influenza Vaccine in a Pediatric Patient With Polymorphic Maculopapular Cutaneous Mastocytosis
por: Sarcina, Davide, et al.
Publicado: (2021)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
por: Naficy, Abdi, et al.
Publicado: (2023)

Bullous eczema presenting as bullous pemphigoid-like eruption: A case series
por: Atteh, George, et al.
Publicado: (2021)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
por: Dagnew, Alemnew F., et al.
Publicado: (2021)

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
por: Teng, Lida, et al.
Publicado: (2022)

Histopathological analysis of vesicular and bullous lesions in Kaposi sarcoma
por: Kandemir, Nilüfer Onak, et al.
Publicado: (2012)

Azithromycin induced bullous fixed drug eruption
por: Das, Anupam, et al.
Publicado: (2016)

Cyclosporine in Generalized Bullous-Fixed Drug Eruption
por: Beniwal, Ranjana, et al.
Publicado: (2018)

Loxoprofen‐induced bullous fixed drug eruption
por: Yamada, Takayuki, et al.
Publicado: (2019)

Bullous drug eruption with low dose methotrexate
por: Yuce Inel, Tuba
Publicado: (2021)

Nicotine-induced bullous fixed drug eruption
por: Sargent, Brynn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84uvhq580uqd7ejd4hcei1tuj9